Trials / Completed
CompletedNCT05537207
Laser at Lumbar Acupoint on Pain and Quality of Life in Chronic Pelvic Pain
Effect of Laser at Lumbar Sensitized Acupoint on Pain Perception and Quality of Life in Female Chronic Pelvic Pain
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- October 6 University · Academic / Other
- Sex
- Female
- Age
- 25 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the effect of low-level laser at lumbar sensitized acupoint on pain perception in chronic pelvic pain. BACKGROUND: chronic pelvic pain is one of the serious problems in the female, resulting in pain and less physical activity.
Detailed description
Thirty six females with chronic pelvic pain will participate in this study. The patients will randomly be divided into two equal groups; the control group will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will described by their gynecologist. and the study group received the same treatment and low-level laser at lumbar sensitized Acupoint, three times per week for four weeks. The evaluation methods by visual analogue scale (VAS), pain sensitivity was evaluated by measuring mean values of pressure pain thresholds (PPT) using a Pressure Algometer, while the quality of life was evaluated by the 12-Item Short-Form Health Survey (SF-12) before and after the treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | low level laser therapy | low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2 |
| OTHER | non-steroidal drugs | All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist. |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2022-12-15
- Completion
- 2023-01-30
- First posted
- 2022-09-13
- Last updated
- 2025-02-11
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05537207. Inclusion in this directory is not an endorsement.